MLN0128 (formerly TAK-228) is a selective ATP-competitive mTORC1/2 inhibitor that induces apoptosis in cell lines with amplified AKT/mTOR signaling, including AML cell lines, without affecting healthy cells [42]. This evidence concerns the gene MTOR and acute myeloid leukemia.